# Project Overview

# TCGA-BRCA Breast Cancer Subtyping Using Transcriptomics

## Introduction

Breast cancer is one of the most heterogeneous human malignancies, consisting of multiple molecular subtypes with distinct biological characteristics, clinical outcomes, and therapeutic responses.

Advances in high-throughput sequencing technologies have enabled transcriptome-wide profiling of tumors, allowing researchers to classify cancers based on gene expression patterns rather than solely histopathological features.

This project presents a computational transcriptomics workflow for identifying molecular breast cancer subtypes using TCGA-BRCA RNA-seq data.

---

# Project Goals

The primary objectives of this project were:

- Analyze large-scale TCGA-BRCA RNA-seq datasets
- Identify molecularly distinct breast cancer subtypes
- Explore transcriptomic heterogeneity among tumors
- Perform subtype-specific survival analysis
- Detect biologically relevant biomarkers
- Investigate enriched biological pathways
- Generate publication-quality visualizations
- Build a reproducible bioinformatics workflow

---

# Scientific Background

## Molecular Subtypes of Breast Cancer

Breast cancer is commonly categorized into molecular subtypes including:

| Subtype | Characteristics |
|---|---|
| Luminal A | Hormone receptor positive, lower proliferation |
| Luminal B | Hormone receptor positive with higher proliferation |
| HER2-enriched | ERBB2 amplification |
| Basal-like | Triple-negative, aggressive phenotype |

These subtypes differ in:

- Prognosis
- Therapeutic response
- Genomic alterations
- Transcriptomic signatures

---

# Why Transcriptomics?

Transcriptomic profiling provides insights into:

- Gene activity
- Tumor biology
- Signaling pathways
- Cellular differentiation
- Tumor aggressiveness

RNA-seq based analysis enables comprehensive characterization of tumor molecular states.

---

# Dataset

## Data Source

- TCGA-BRCA
- GDC Data Portal

## Data Included

- RNA-seq gene expression
- Clinical survival metadata

## Cohort Size

Approximately 1120 breast cancer samples were analyzed.

---

# Computational Strategy

The workflow integrated:

- Gene expression normalization
- Principal component analysis (PCA)
- K-means clustering
- Subtype annotation
- Survival analysis
- Differential expression analysis
- Pathway enrichment analysis

This approach allowed identification of biologically meaningful tumor groups.

---

# Biological Insights

The analysis identified subtype-associated expression patterns involving:

- ESR1
- PGR
- ERBB2
- EGFR
- KRT5
- GATA3
- FOXA1

These biomarkers correspond to well-established breast cancer molecular phenotypes.

---

# Clinical Relevance

Transcriptomic subtype classification has major implications for:

- Prognosis prediction
- Precision medicine
- Therapeutic selection
- Biomarker discovery
- Cancer stratification

The survival analysis further demonstrated clinically relevant subtype-associated trends.

---

# Project Outcomes

This project successfully generated:

- Molecular subtype clusters
- PCA subtype visualization
- Survival curves
- Differential expression results
- Volcano plots
- Marker heatmaps
- Pathway enrichment results
- Integrated publication-style figures

---

# Research Applications

The workflow can be extended for:

- Multi-omics integration
- Drug response prediction
- Machine learning classification
- Precision oncology studies
- Biomarker discovery pipelines

---

# Technical Significance

This project demonstrates integration of:

- Bioinformatics
- Machine learning
- Cancer genomics
- Clinical data analysis
- Computational biology

within a reproducible transcriptomics framework.

---

# Conclusion

This study highlights the power of transcriptomic profiling for understanding breast cancer heterogeneity and identifying clinically meaningful molecular subtypes.

The project serves as a foundation for future integrative cancer genomics and precision medicine research.
